Medpace Reports Strong Q1 Growth with 26.5% Revenue Surge

Medpace Holdings, Inc. (MEDP) has reported a robust start to the 2026 fiscal year, delivering a first-quarter profit increase driven by substantial top-line growth. The results highlight the company's expanding footprint in the clinical research space, with revenue climbing significantly compared to the same period last year. For the first quarter, the company's earnings reached $123.87 million, translating to $4.28 per share. This represents a notable increase from the $114.59 million, or $3.67 per share, reported in the prior year's first quarter. Revenue for the period surged 26.5% to $706.60 million, up from $558.57 million a year ago. Looking ahead, Medpace issued full-year guidance projecting earnings per share to fall between $16.68 and $17.50. The company expects total annual revenue to be within the range of $2.755 billion to $2.855 billion. These figures suggest strong demand for the company's clinical research services, positioning the firm for continued growth throughout the remainder of the fiscal year. The combination of double-digit revenue growth and improved bottom-line performance indicates efficient scaling of operations.